TY - JOUR AU - Mészáros, Mária AU - Porkoláb, Gergő AU - Kiss, Lóránd AU - Pilbat, Ana Maria AU - Kóta, Zoltán AU - Kupihár, Zoltán AU - Kéri, Albert AU - Galbács, Gábor AU - Siklós, László AU - Tóth, András AU - Fülöp, Lívia AU - Czirjákné Csete, Mária AU - Sipos, Áron AU - Hulper, P AU - Sipos, Péter AU - Páli, Tibor AU - Rákhely, Gábor AU - Révész, Piroska AU - Deli, Mária Anna AU - Veszelka, Szilvia TI - Niosomes decorated with dual ligands targeting brain endothelial transporters increase cargo penetration across the blood-brain barrier JF - EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES J2 - EUR J PHARM SCI VL - 123 ET - 0 PY - 2018 SP - 228 EP - 240 PG - 13 SN - 0928-0987 DO - 10.1016/j.ejps.2018.07.042 UR - https://m2.mtmt.hu/api/publication/3399566 ID - 3399566 AB - Nanoparticles targeting transporters of the blood-brain barrier (BBB) are promising candidates to increase the brain penetration of biopharmacons. Solute carriers (SLC) are expressed at high levels in brain endothelial cells and show a specific pattern at the BBB. The aim of our study was to test glutathione and ligands of SLC transporters as single or dual BBB targeting molecules for nanovesicles. High mRNA expression levels for hexose and neutral amino acid transporting SLCs were found in isolated rat brain microvessels and our rat primary cell based co-culture BBB model. Niosomes were derivatized with glutathione and SLC ligands glucopyranose and alanine. Serum albumin complexed with Evans blue (67kDa), which has a very low BBB penetration, was selected as a cargo. The presence of targeting ligands on niosomes, especially dual labeling, increased the uptake of the cargo molecule in cultured brain endothelial cells. This cellular uptake was temperature dependent and could be decreased with a metabolic inhibitor and endocytosis blockers filipin and cytochalasin D. Making the negative surface charge of brain endothelial cells more positive with a cationic lipid or digesting the glycocalyx with neuraminidase elevated the uptake of the cargo after treatment with targeted nanocarriers. Treatment with niosomes increased plasma membrane fluidity, suggesting the fusion of nanovesicles with endothelial cell membranes. Targeting ligands elevated the permeability of the cargo across the BBB in the culture model and in mice, and dual-ligand decoration of niosomes was more effective than single ligand labeling. Our data indicate that dual labeling with ligands of multiple SLC transporters can potentially be exploited for BBB targeting of nanoparticles. LA - English DB - MTMT ER - TY - JOUR AU - Kiss, Lóránd AU - Bocsik, Alexandra AU - Walter, Fruzsina AU - Ross, J AU - Brown, D AU - Mendenhall, BA AU - Crews, SR AU - Lowry, J AU - Coronado, V AU - Thompson, DE AU - Sipos, Péter AU - Révész, Piroska AU - Deli, Mária Anna AU - Petrikovics, I TI - In Vitro and In Vivo Blood-Brain Barrier Penetration Studies with the Novel Cyanide Antidote Candidate Dimethyl Trisulfide in Mice JF - TOXICOLOGICAL SCIENCES J2 - TOXICOL SCI VL - 160 PY - 2017 IS - 2 SP - 398 EP - 407 PG - 10 SN - 1096-6080 DO - 10.1093/toxsci/kfx190 UR - https://m2.mtmt.hu/api/publication/3305693 ID - 3305693 AB - Recent in vitro and in vivo studies highlight the strong potential of dimethyl trisulfide (DMTS) as an antidote for cyanide (CN) intoxication. Due to its high oxygen demand, the brain is one of the main target organs of CN. The blood-brain barrier (BBB) regulates the uptake of molecules into the brain. In the literature, there is no data about the ability of DMTS to penetrate the BBB. Therefore, our aim was to test the in vitro BBB penetration of DMTS and its in vivo pharmacokinetics in blood and brain. The in vitro BBB penetration of DMTS was measured by using a parallel artificial membrane permeability assay (BBB-PAMPA), and a triple BBB co-culture model. The pharmacokinetics was investigated in a mouse model by following the DMTS concentration in blood and brain at regular time intervals following intramuscular administration. DMTS showed high penetrability in both in vitro systems (apparent permeability coefficients: BBB-PAMPA 11.8 x 10(-6) cm/s; cell culture 158 x 10(-6) cm/s) without causing cell toxicity and leaving the cellular barrier intact. DMTS immediately absorbed into the blood after the intramuscular injection (5 min), and rapidly penetrated the brain of mice (10 min). In addition to the observed passive diffusion in the in vitro studies, the contribution of facilitated and/or active transport to the measured high permeability of DMTS in the pharmacokinetic studies can be hypothesized. Earlier investigations demonstrating the antidotal efficacy of DMTS against CN together with the present results highlight the promise of DMTS as a brain-protective CN antidote. LA - English DB - MTMT ER - TY - JOUR AU - Gyuris, Márió AU - Hackler, László AU - Nagy, Lajos István AU - Alföldi, Róbert AU - Rédei, Eszter AU - Marton, Annamária AU - Vellai, Tibor AU - Faragó, Nóra AU - Ózsvári, Béla AU - Hetényi, Anasztázia AU - Tóth, Gábor K AU - Sipos, Péter AU - Kanizsai, Iván AU - Puskás, László TI - Mannich Curcuminoids as Potent Anticancer Agents JF - ARCHIV DER PHARMAZIE J2 - ARCH PHARM VL - 350 PY - 2017 IS - 7 PG - 22 SN - 0365-6233 DO - 10.1002/ardp.201700005 UR - https://m2.mtmt.hu/api/publication/3229024 ID - 3229024 N1 - Funding Agency and Grant Number: [GOP-1.1.1-11-2011-0003]\n Funding text: This work was supported by the following grant: GOP-1.1.1-11-2011-0003.\n AB - A series of novel curcuminoids were synthesised for the first time via a Mannich-3CR/organocatalysed Claisen–Schmidt condensation sequence. Structure–activity relationship (SAR) studies were performed by applying viability assays and holographic microscopic imaging to these curcumin analogues for anti-proliferative activity against A549 and H1975 lung adenocarcinoma cells. The TNFα-induced NF-κB inhibition and autophagy induction effects correlated strongly with the cytotoxic potential of the analogues. Significant inhibition of tumour growth was observed when the most potent analogue 44 was added in liposomes at one-sixth of the maximally tolerated dose in the A549 xenograft model. The novel spectrum of activity of these Mannich curcuminoids warrants further preclinical investigations. LA - English DB - MTMT ER - TY - JOUR AU - Horváth, Tamás AU - Ambrus, Rita AU - Völgyi, Gergely AU - Budai-Szűcs, Mária AU - Márki, Árpád AU - Sipos, Péter AU - Bartos, Csilla AU - Seres, Adrienn AU - Sztojkov-Ivanov, Anita AU - Takácsné Novák, Krisztina AU - Csányi, Erzsébet AU - Gáspár, Róbert AU - Révész, Piroska TI - Effect of solubility enhancement on nasal absorption of meloxicam JF - EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES J2 - EUR J PHARM SCI VL - 95 PY - 2016 SP - 96 EP - 102 PG - 7 SN - 0928-0987 DO - 10.1016/j.ejps.2016.05.031 UR - https://m2.mtmt.hu/api/publication/3076538 ID - 3076538 N1 - \n Department of Pharmaceutical Technology, University of Szeged, Szeged, Hungary \n Goodwill Pharma Ltd., Szeged, Hungary \n Department of Pharmacodynamics and Biopharmacy, University of Szeged, Szeged, Hungary \n Department of Pharmaceutical Chemistry, Semmelweis University, Budapest, Hungary \n Cited By :3 \n Export Date: 20 November 2018 \n CODEN: EPSCE \n Correspondence Address: Szabó-Révész, P.; Department of Pharmaceutical Technology, University of Szeged, Eötvös u. 6, Hungary Department of Pharmaceutical Technology, University of Szeged, Szeged, Hungary Goodwill Pharma Ltd., Szeged, Hungary Department of Pharmacodynamics and Biopharmacy, University of Szeged, Szeged, Hungary Department of Pharmaceutical Chemistry, Semmelweis University, Budapest, Hungary Cited By :11 Export Date: 2 February 2021 CODEN: EPSCE Correspondence Address: Szabó-Révész, P.; Department of Pharmaceutical Technology, Eötvös u. 6, Hungary Chemicals/CAS: meloxicam, 71125-38-7; Anti-Inflammatory Agents, Non-Steroidal; meloxicam; Thiazines; Thiazoles Manufacturers: Egis, Hungary Department of Pharmaceutical Technology, University of Szeged, Szeged, Hungary Goodwill Pharma Ltd., Szeged, Hungary Department of Pharmacodynamics and Biopharmacy, University of Szeged, Szeged, Hungary Department of Pharmaceutical Chemistry, Semmelweis University, Budapest, Hungary Cited By :12 Export Date: 1 June 2021 CODEN: EPSCE Correspondence Address: Szabó-Révész, P.; Department of Pharmaceutical Technology, Eötvös u. 6, Hungary Chemicals/CAS: meloxicam, 71125-38-7; Anti-Inflammatory Agents, Non-Steroidal; meloxicam; Thiazines; Thiazoles Manufacturers: Egis, Hungary AB - Besides the opioids the standard management of the World Health Organization suggests NSAIDs (non-steroidal anti-inflammatory drugs) alone or in combination to enhance analgesia in malignant and non-malignant pain therapy. The applicability of NSAIDs in a nasal formulation is a new approach in pharmaceutical technology. In order to enhance the nasal absorption of meloxicam (MX) as an NSAID, its salt form, meloxicam potassium monohydrate (MXP), registered by Egis Plc., was investigated in comparison with MX. The physico-chemical properties of the drugs (structural analysis, solubility and dissolution rate) and the mucoadhesivity of nasal formulations were controlled. In vitro and in vivo studies were carried out to determine the nasal applicability of MXP as a drug candidate in pain therapy. It can be concluded that MX and MXP demonstrated the same equilibrium solubility at the pH5.60 of the nasal mucosa (0.017mg/ml); nonetheless, MXP indicated faster dissolution and a higher permeability through the synthetic membrane. The animal studies justified the short Tmax value (15min) and the high AUC of MXP, which is important in acute pain therapy. It can be assumed that the low mucoadhesivity of MXP spray did not increase the residence time in the nasal cavity, and the elimination from the nasal mucosa was therefore faster than in the case of MX. Further experiments are necessary to prove the therapeutic relevance of this MXP-containing innovative intranasal formulation. LA - English DB - MTMT ER - TY - JOUR AU - Hackler, L Jr AU - Ózsvári, Béla AU - Gyuris, M AU - Sipos, Péter AU - Fábián, Gabriella AU - Molnár, Eszter AU - Marton, Annamária AU - Faragó, Nóra AU - Mihály, József AU - Nagy, Lajos István AU - Szénási, Tibor AU - Diron, A AU - Párducz, Árpád AU - Kanizsai, Iván AU - Puskás, László TI - The Curcumin Analog C-150, Influencing NF-kappaB, UPR and Akt/Notch Pathways Has Potent Anticancer Activity In Vitro and In Vivo. JF - PLOS ONE J2 - PLOS ONE VL - 11 PY - 2016 IS - 3 PG - 16 SN - 1932-6203 DO - 10.1371/journal.pone.0149832 UR - https://m2.mtmt.hu/api/publication/3032868 ID - 3032868 N1 - AVIDIN Ltd., Szeged, Hungary Department of Pharmaceutical Technology, University of Szeged, Szeged, Hungary AVICOR Ltd., Szeged, Hungary Institute of Biochemistry, Biological Research Center, Hungarian Academy of Sciences, Szeged, Hungary Institute of Genetics, Biological Research Center, Hungarian Academy of Sciences, Szeged, Hungary Institute of Biophysics, Biological Research Center, Hungarian Academy of Sciences, Szeged, Hungary Cited By :32 Export Date: 3 May 2022 CODEN: POLNC Chemicals/CAS: curcumin, 458-37-7; protein kinase B, 148640-14-6; Acrylamides; Antineoplastic Agents; C-150 curcumin; Curcumin; NF-kappa B; Proto-Oncogene Proteins c-akt; Receptors, Notch Tradenames: c 150 AB - C-150 a Mannich-type curcumin derivative, exhibited pronounced cytotoxic effects against eight glioma cell lines at micromolar concentrations. Inhibition of cell proliferation by C-150 was mediated by affecting multiple targets as confirmed at transcription and protein level. C-150 effectively reduced the transcription activation of NFkB, inhibited PKC-alpha which are constitutively over-expressed in glioblastoma. The effects of C-150 on the Akt/ Notch signaling were also demonstrated in a Drosophila tumorigenesis model. C-150 reduced the number of tumors in Drosophila with similar efficacy to mitoxantrone. In an in vivo orthotopic glioma model, C-150 significantly increased the median survival of treated nude rats compared to control animals. The multi-target action of C-150, and its preliminary in vivo efficacy would render this curcumin analogue as a potent clinical candidate against glioblastoma. LA - English DB - MTMT ER - TY - JOUR AU - Katona, Gábor AU - Sipos, Péter AU - Patrick, Frohberg AU - Joachim, Ulrich AU - Révész, Piroska AU - Jójártné Laczkovich, Orsolya TI - Study of paracetamol-containing pastilles produced by melt technology JF - JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY J2 - J THERM ANAL CALORIM VL - 123 PY - 2016 IS - 3 SP - 2549 EP - 2559 PG - 11 SN - 1388-6150 DO - 10.1007/s10973-015-5223-7 UR - https://m2.mtmt.hu/api/publication/3025028 ID - 3025028 N1 - Department of Pharmaceutical Technology, University of Szeged, Eötvös 6, Szeged, 6720, Hungary Centre of Engineering Science, Thermal Process Engineering, Martin Luther University Halle-Wittenberg, Halle, 06099, Germany Richter Gedeon Plc., Budapest, Gyömroi 19-21, Budapest, 1103, Hungary Cited By :6 Export Date: 14 October 2020 CODEN: JTACF Correspondence Address: Szabó-Révész, P.; Department of Pharmaceutical Technology, University of Szeged, Eötvös 6, Hungary; email: revesz@pharm.u-szeged.hu LA - English DB - MTMT ER - TY - JOUR AU - Balázs, Boglárka AU - Sipos, Péter AU - Corina, Danciu AU - Stefana, Avram AU - Codruta, Soica AU - Cristina, Dehelean AU - Gábor, Varju AU - Erős, Gábor AU - Budai-Szűcs, Mária AU - Berkó, Szilvia AU - Csányi, Erzsébet TI - ATR-FTIR and Raman spectroscopic investigation of the electroporation-mediated transdermal delivery of a nanocarrier system containing an antitumour drug JF - BIOMEDICAL OPTICS EXPRESS J2 - BIOMED OPT EXPRESS VL - 7 PY - 2016 IS - 1 SP - 67 EP - 78 PG - 12 SN - 2156-7085 DO - 10.1364/BOE.7.000067 UR - https://m2.mtmt.hu/api/publication/2981310 ID - 2981310 N1 - Department of Pharmaceutical Technology, University of Szeged, Szeged, H-6720, Hungary Gedeon Richter Plc, Budapest, H-1103, Hungary Department of Pharmacognosy, ‘Victor Babes’ University of Medicine and Pharmacy, Timisoara, 300041, Romania Discipline of Pharmacology, ‘Victor Babes’ University of Medicine and Pharmacy, Timisoara, 300041, Romania Discipline of Pharmaceutical Chemistry, ‘Victor Babes’ University of Medicine and Pharmacy, Timisoara, 300041, Romania Department of Toxicology, ‘Victor Babes’ University of Medicine and Pharmacy, Timisoara, 300041, Romania Dr. Derm Clinic of Anti-Aging Dermatology, Aesthetic Laser and Plastic Surgery, Budapest, H-1026, Hungary Department of Dermatology and Allergology, University of Szeged, Szeged, H-6720, Hungary Department of Oral Biology and Experimental Dental Research, University of Szeged, Szeged, H-6720, Hungary Cited By :15 Export Date: 11 January 2020 Chemicals/CAS: cremophor, 39279-69-1, 51142-51-9; genistein, 446-72-0; myristic acid isopropyl ester, 110-27-0 Department of Pharmaceutical Technology, University of Szeged, Szeged, H-6720, Hungary Gedeon Richter Plc, Budapest, H-1103, Hungary Department of Pharmacognosy, ‘Victor Babes’ University of Medicine and Pharmacy, Timisoara, 300041, Romania Discipline of Pharmacology, ‘Victor Babes’ University of Medicine and Pharmacy, Timisoara, 300041, Romania Discipline of Pharmaceutical Chemistry, ‘Victor Babes’ University of Medicine and Pharmacy, Timisoara, 300041, Romania Department of Toxicology, ‘Victor Babes’ University of Medicine and Pharmacy, Timisoara, 300041, Romania Dr. Derm Clinic of Anti-Aging Dermatology, Aesthetic Laser and Plastic Surgery, Budapest, H-1026, Hungary Department of Dermatology and Allergology, University of Szeged, Szeged, H-6720, Hungary Department of Oral Biology and Experimental Dental Research, University of Szeged, Szeged, H-6720, Hungary Cited By :15 Export Date: 13 January 2020 Chemicals/CAS: cremophor, 39279-69-1, 51142-51-9; genistein, 446-72-0; myristic acid isopropyl ester, 110-27-0 LA - English DB - MTMT ER - TY - BOOK AU - Ambrus, Rita AU - Berkó, Szilvia AU - Pannonhalminé Csóka, Ildikó AU - Sipos, Péter AU - Pallagi, Edina AU - Jójártné Laczkovich, Orsolya AU - Révész, Piroska TI - Gyógyszer-nanotechnológia. kurzus-háttéranyag TS - kurzus-háttéranyag PB - Szegedi Tudományegyetem (SZTE) CY - Szeged PY - 2015 SP - 151 UR - https://m2.mtmt.hu/api/publication/30885433 ID - 30885433 LA - Hungarian DB - MTMT ER - TY - BOOK AU - Aigner, Zoltán AU - Ambrus, Rita AU - Regdon, Géza (ifj.) AU - Sipos, Péter AU - Sovány, Tamás ED - Aigner, Zoltán ED - Révész, Piroska TI - Hatóanyagok, segédanyagok és gyógyszerkészítmények műszeres vizsgálata. gyakorlati jegyzet TS - gyakorlati jegyzet PB - Szegedi Tudományegyetem (SZTE) CY - Szeged PY - 2015 SP - 114 UR - https://m2.mtmt.hu/api/publication/2977631 ID - 2977631 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Bartos, Csilla AU - Ambrus, Rita AU - Sipos, Péter AU - Budai-Szűcs, Mária AU - Csányi, Erzsébet AU - Gáspár, Róbert AU - Márki, Árpád AU - Seres, Adrienn AU - Sztojkov-Ivanov, Anita AU - Horváth, Tamás AU - Révész, Piroska TI - Study of sodium hyaluronate-based intranasal formulations containing micro- or nanosized meloxicam particles JF - INTERNATIONAL JOURNAL OF PHARMACEUTICS J2 - INT J PHARM VL - 491 PY - 2015 IS - 1-2 SP - 198 EP - 207 PG - 10 SN - 0378-5173 DO - 10.1016/j.ijpharm.2015.06.046 UR - https://m2.mtmt.hu/api/publication/2917042 ID - 2917042 N1 - Department of Pharmaceutical Technology, Universi- Ty of Szeged H-6720 Szeged, University of Szeged, Eötvös u. 6, Szeged, Hungary Richter Gedeon Nyrt., Budapest, Hungary Department of Pharmacodynamics and Biopharmacy, University of Szeged, Szeged, Hungary Cited By :21 Export Date: 2 February 2021 CODEN: IJPHD Correspondence Address: Szabó-Révész, P.; Department of Pharmaceutical Technology, Eötvös u. 6, Hungary; email: revesz@pharm.u-szeged.hu Chemicals/CAS: hyaluronic acid, 31799-91-4, 9004-61-9, 9067-32-7; meloxicam, 71125-38-7; piroxicam, 36322-90-4; polyvinyl alcohol, 37380-95-3, 9002-89-5; Anti-Inflammatory Agents, Non-Steroidal; Excipients; Hyaluronic Acid; meloxicam; Membranes, Artificial; Polyvinyl Alcohol; Thiazines; Thiazoles LA - English DB - MTMT ER -